Gilbert Tang, MD, surgical director of the structural heart program at the Mount Sinai Health System, discussed a key challenge care teams often encounter during tricuspid valve procedures.
Cardiovascular Business spoke with cardiologist Daniel Judge, MD, about the long-term benefits of acoramidis, a new drug therapy that just received FDA approval to treat transthyretin amyloid cardiomyopathy.
Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.
Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.
Jim Melton, DO, a vascular surgeon in Oklahoma City, explains his efforts to reach patients in rural Oklahoma and Native American tribes with a mobile cardiovascular clinic program.
The way a cardiology department's management is organized can have a direct impact on physician satisfaction and patient care. "Without good governance and leadership, nothing else matters," one expert said.
Vivek Reddy, MD, was involved in most of the late-breaking pulsed field ablation trials at Heart Rhythm 2024. He spoke to Cardiovascular Business at the conference about those trials and what they mean going forward.
Ascension Health in Texas uses AI that can read CT scans for stroke and pulmonary embolism to activate care teams before the images even get into the PACS.
Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.
